[go: up one dir, main page]

ECSP19059553A - Anticuerpos anti-tgf-beta y su uso - Google Patents

Anticuerpos anti-tgf-beta y su uso

Info

Publication number
ECSP19059553A
ECSP19059553A ECSENADI201959553A ECDI201959553A ECSP19059553A EC SP19059553 A ECSP19059553 A EC SP19059553A EC SENADI201959553 A ECSENADI201959553 A EC SENADI201959553A EC DI201959553 A ECDI201959553 A EC DI201959553A EC SP19059553 A ECSP19059553 A EC SP19059553A
Authority
EC
Ecuador
Prior art keywords
tgf
antibody
beta antibodies
conditions
antibodies
Prior art date
Application number
ECSENADI201959553A
Other languages
English (en)
Inventor
Patrick Finn
Rao Koduri
Parminder Mankoo
Natalia Malkova
Richard Gregory
Gary Shapiro
Marcella Yu
Christopher Winter
Kevin Browen
Huawei Qiu
Joachim Theilhaber
Feng Liu
Jack Pollard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP19059553A publication Critical patent/ECSP19059553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona un anticuerpo pan-TGF-B; mejorado para el tratamiento de afecciones que están mediadas por TGF-B, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1.
ECSENADI201959553A 2017-01-20 2019-08-19 Anticuerpos anti-tgf-beta y su uso ECSP19059553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061 2017-01-20

Publications (1)

Publication Number Publication Date
ECSP19059553A true ECSP19059553A (es) 2019-08-30

Family

ID=61656071

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201959553A ECSP19059553A (es) 2017-01-20 2019-08-19 Anticuerpos anti-tgf-beta y su uso

Country Status (22)

Country Link
US (4) US10766955B2 (es)
JP (3) JP7213186B2 (es)
CN (2) CN110520441B8 (es)
AU (2) AU2018209391B2 (es)
BR (1) BR112019014787A2 (es)
CA (1) CA3050845A1 (es)
CL (1) CL2019002011A1 (es)
CO (1) CO2019008946A2 (es)
CR (1) CR20190375A (es)
DO (1) DOP2019000191A (es)
EC (1) ECSP19059553A (es)
IL (3) IL268112B2 (es)
MA (1) MA47311A (es)
MX (2) MX2019008551A (es)
MY (1) MY200751A (es)
NZ (1) NZ796440A (es)
PE (1) PE20200734A1 (es)
PH (1) PH12019501635A1 (es)
SG (1) SG11201906660TA (es)
TW (3) TWI856437B (es)
UY (1) UY37575A (es)
ZA (1) ZA201904494B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
EP3820575A1 (en) * 2018-07-10 2021-05-19 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
CA3124415A1 (en) * 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
KR20220140572A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 조절 t 세포를 활성화시키는 방법
EP4103600A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Chromatography resin and uses thereof
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CA3224018A1 (en) 2021-06-18 2022-12-22 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
CA3227318A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
AU2023254108B2 (en) 2022-04-13 2026-01-29 Immunitybio, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
ZA200505306B (en) 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PT3404102T (pt) 2004-04-21 2021-09-16 Alexion Pharma Inc Conjugados de entrega óssea e método de usar os mesmos para direcionar as proteínas ao osso
PT1850873T (pt) 2005-02-08 2019-02-19 Genzyme Corp Anticorpos contra tgfbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP2164873B2 (en) 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
PT2379600E (pt) 2008-12-22 2014-04-29 Novo Nordisk As Anticorpos contra inibidor da via de fator tecidual
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
PL2714735T3 (pl) 2011-06-03 2022-02-21 Xoma Technology Ltd. Przeciwciała swoiste dla tgf-beta
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9944712B2 (en) 2012-05-31 2018-04-17 Innate Pharma TLR3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014062978A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
MX369360B (es) 2013-03-20 2019-11-06 Baylor College Medicine ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
KR20240017102A (ko) * 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
JP6877339B2 (ja) * 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
DK3283107T3 (da) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
ES3028883T3 (en) 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途

Also Published As

Publication number Publication date
AU2024264593A1 (en) 2024-12-05
JP7411832B2 (ja) 2024-01-11
US20220195026A1 (en) 2022-06-23
CN117417939A (zh) 2024-01-19
AU2018209391B2 (en) 2024-08-15
MX2023002588A (es) 2023-03-22
US20250026821A1 (en) 2025-01-23
CO2019008946A2 (es) 2019-09-30
SG11201906660TA (en) 2019-08-27
US12049496B2 (en) 2024-07-30
BR112019014787A2 (pt) 2020-02-27
NZ756431A (en) 2025-03-28
PE20200734A1 (es) 2020-07-23
IL323799A (en) 2025-12-01
TWI787230B (zh) 2022-12-21
AU2018209391A1 (en) 2019-09-05
ZA201904494B (en) 2020-12-23
CR20190375A (es) 2019-12-17
CA3050845A1 (en) 2018-07-26
US10766955B2 (en) 2020-09-08
MY200751A (en) 2024-01-13
US20180244763A1 (en) 2018-08-30
MA47311A (fr) 2019-11-27
JP2020514310A (ja) 2020-05-21
UY37575A (es) 2018-10-31
US20200399358A1 (en) 2020-12-24
CL2019002011A1 (es) 2019-11-22
IL311866B1 (en) 2025-11-01
CN110520441B (zh) 2023-11-14
TW202506185A (zh) 2025-02-16
IL311866A (en) 2024-06-01
PH12019501635A1 (en) 2019-11-04
JP7213186B2 (ja) 2023-01-26
NZ796440A (en) 2025-12-19
TW201833135A (zh) 2018-09-16
US11242384B2 (en) 2022-02-08
TWI856437B (zh) 2024-09-21
CN110520441B8 (zh) 2024-07-09
CN117417939A8 (zh) 2024-07-12
TW202313678A (zh) 2023-04-01
CN110520441A (zh) 2019-11-29
IL268112B1 (en) 2025-05-01
JP2023052376A (ja) 2023-04-11
JP2024038040A (ja) 2024-03-19
MX2019008551A (es) 2020-01-27
IL268112B2 (en) 2025-09-01
DOP2019000191A (es) 2019-10-15
IL268112A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
CL2018000947S1 (es) Automóvil
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
GT201700104A (es) Agonistas parciales del receptor de insulina
MX387055B (es) Agonistas del receptor de apelina (apj) y usos de los mismos.
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CO2017003005A2 (es) Anticuerpos anti-mfi2
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
ECSP21001786A (es) Degradadores selectivos del receptor de estrógeno
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
CL2018000791S1 (es) Automóvil
TH1901004394A (th) แอนติบอดีต้าน-tgf-เบต้า และการใช้ของพวกมัน
EA201990505A1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации
AR102495A1 (es) Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso